In many parts of the world, incidence of papillary thyroid cancer is increasing faster than any
other malignancy. Most papillary thyroid cancers that are diagnosed are small and are …

The use of radioactive iodine (131 I) for the treatment of thyroid carcinoma has changed over
the past 50 y. These changes are based on increasing awareness of the biophysical …

Thyroid nodules are approximately 4 times more common in women than in men. Palpable
nodules increase in frequency throughout life, reaching a prevalence of approximately 5% in …

Context Substantial uncertainty persists about the indications for radioactive iodine for
thyroid cancer. Use of radioactive iodine over time and the correlates of its use remain …

Use of radioactive iodine is an essential adjuvant treatment strategy after thyroidectomy in
patients with differentiated thyroid carcinoma. Although generally safe, radioiodine therapy …

Well under 15% of differentiated thyroid carcinoma (DTC) is diagnosed at≤ 18 years of age.
The population is heterogenous and the differences between prepubertal children and …

Radioactive iodine (RAI) in the form of 131 I has been used to treat thyroid cancer since
1946. RAI is used after thyroidectomy to ablate the residual normal thyroid remnant, as …

The role of radiotherapy in ophthalmic practice continues to grow. This growth has seen an
expansion of indications for radiotherapy, a refinement of the modalities that can be used …

Controversy exists over optimal management of low-risk differentiated thyroid cancer. This
controversy occurs in all aspects of management, including surgery, use of radioactive …

Management recommendations for differentiated thyroid cancer are evolving. Total
thyroidectomy is the backbone of curative-intent therapy, with radioiodine ablation (RAI) of …